然人 上述股东关联关系或一致行动的说明 公司未知以上前十名无限售条件股东之间是否存在 关联关系或一致行动人关系 | 华丽家族股份有限公司2025 年半年度报告摘要 | | | | --- | --- | --- | | 公司代码：600503 公司简称：华丽家族 | | | | 华丽家族股份有限公司 | | | | 年半年度报告摘要 | 华丽家族股份有限公司2025 | | | 第一节 | 重要提示 | | | 展规划，投资者应当到 网站仔细阅读半年度报告全文。 | www.sse.com.cn | | | 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 | | | | 无 | | | | 第二节 | 公司基本情况 | | | 公司股票简况 | | | | 股票种类 | 股票上市交易所 股票简称 | 股票代码 变更前股票 | | 简称 | | | | A股 | 上海证券交易所 华丽家族 | 600503 SST新智 | | 联系人和联系方式 | 董事会秘书 | 证券事务代表 | | 姓名 | 娄欣 | 方治博 | | 电话 | 021-62376199 | 021-62376199 ...

格隆汇8月26日丨华丽家族(600503.SH)公布2025年半年度报告，报告期实现营业收入1.38亿元，同比下 降11.76%；归属于上市公司股东的净利润-1041.24万元；基本每股收益-0.0065元。 ...

华丽家族股份有限公司2025 年半年度报告 公司代码：600503 公司简称：华丽家族 华丽家族股份有限公司 2025 年半年度报告 1 / 147 华丽家族股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人王伟林、主管会计工作负责人王坚忠及会计机构负责人（会计主管人员）姚基 勇声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中所涉及的未来计划、发展战略等前瞻性描述不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 七、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 十、 重大风险提示 报告期内， ...

New Stock Issuance - New stock issuance for Huaxin Jingke at a price of 18.60 on August 25, 2025[1] - Shenkou Co. (stock code: 002633) has a tender offer period from July 29 to August 27, 2025[1] - Fushun Special Steel (stock code: 600399) has a tender offer period from August 12 to September 10, 2025[1] Market Alerts - Dongxin Co. (stock code: 688110) reported severe abnormal fluctuations on August 16, 2025[1] - ST Suwu (stock code: 600200) and ST Zhongdi (stock code: 000609) both have announcements dated August 25, 2025[1] - Multiple companies including Zhehai Deman (stock code: 688577) and Huaguang Huaneng (stock code: 600475) have announcements related to abnormal fluctuations on August 23, 2025[1] Additional Information - The report includes links to detailed announcements for various companies, providing transparency and access to further information[1] - The document highlights the importance of monitoring stock performance and market trends for informed investment decisions[1]

Group 1 - Huali Family plans to invest up to 300 million yuan to acquire 5%-8.09% of Haihe Pharmaceutical's shares, marking a significant move after years of inactivity in external investments [1] - Haihe Pharmaceutical has successfully commercialized three products, including Gumeitini tablets, which received conditional approval from the National Medical Products Administration in March 2023 and was included in the national medical insurance catalog [2] - The company has a strong pipeline with five products in clinical research, including a PI3Kα inhibitor, which has the potential to be the first of its kind for treating ovarian clear cell carcinoma [3] Group 2 - The domestic innovative drug industry is accelerating, with small molecule drugs maintaining an irreplaceable position in clinical treatment due to their oral convenience and controllable production costs [4] - Huali Family's investment in Haihe Pharmaceutical is a strategic move to optimize its business structure amid challenges in the real estate sector, with expectations of Haihe entering a rapid growth phase by 2027 [4] - This investment reflects Huali Family's recognition of Haihe Pharmaceutical's R&D capabilities and commercial prospects, serving as a crucial step for future business transformation [4]

Group 1 - Huayi Family plans to invest up to 300 million CNY to acquire 5%-8.09% of Haihe Pharmaceutical's shares, marking a significant move after years of inactivity in external investments [1] - Haihe Pharmaceutical has successfully commercialized three products, including Gumeitini tablets, which received conditional approval in March 2023 and was included in the national medical insurance directory [2] - The company has a strong pipeline with five products in clinical research, including a PI3Kα inhibitor, indicating potential for growth in unmet clinical needs [3] Group 2 - The domestic innovative drug industry is accelerating, with small molecule drugs maintaining an irreplaceable position in clinical treatment due to their convenience and cost-effectiveness [4] - Huayi Family's investment in Haihe Pharmaceutical is a strategic move to optimize its business structure amid challenges in the real estate sector, aiming for predictable returns as Haihe Pharmaceutical is expected to enter a rapid growth phase by 2027 [4] - This investment reflects Huayi Family's recognition of Haihe Pharmaceutical's R&D capabilities and commercial prospects, serving as a crucial step for future business transformation [4]

华丽家族股份有限公司 2025 年第一次临时股东大会会议资料 2025年第一次临时股东大会 会议资料 二〇二五年八月二十九日 华丽家族股份有限公司 2025 年第一次临时股东大会会议资料 会议议程 一、 会议时间： 现场会议召开时间：2025年8月29日 14点30分 网络投票时间：按照中国证监会和上海证券交易所相关规定 二、 会议地点：上海市松江区石湖荡镇三新公路207号会议室 华丽家族股份有限公司 三、 主持人：董事长王伟林 四、 宣布大会参加人数、代表股数、会议召开、介绍会议出席人员、介绍律师 事务所见证律师 五、 股东审议以下议案： 1、审议《关于现金增资上海海和药物研究开发股份有限公司暨关联交易的议 案》 华丽家族股份有限公司 二〇二五年八月二十九日 六、 股东代表发言及回答股东提问； 七、 大会进行表决； 八、 宣读现场表决结果； 九、 宣布现场会议结束。 华丽家族股份有限公司 2025 年第一次临时股东大会会议资料 议案一 关于现金增资上海海和药物研究开发股份有限公司 华丽家族股份有限公司 2025 年第一次临时股东大会会议资料 暨关联交易的议案 各位股东： 华丽家族股份有限公司（以下简称"公司 ...

New Stock Listings - New stock "能之光" (Code: 920056) listed at an issue price of 7.21 on August 22, 2025[1] - "申科股份" (Code: 002633) has a tender offer period from July 29 to August 27, 2025[1] - "抚顺特钢" (Code: 600399) has a tender offer period from August 12 to September 10, 2025[1] Abnormal Fluctuations - "赛诺医疗" (Code: 688108) reported severe abnormal fluctuations on August 19, 2025[1] - "ST苏吴" (Code: 600200) announced abnormal fluctuations on August 21, 2025[1] - "汇嘉时代" (Code: 603101) reported abnormal fluctuations on August 22, 2025[1] Other Notable Announcements - "酒鬼酒" (Code: 000799) reported an announcement on August 21, 2025[1] - "国机精工" (Code: 002046) had an announcement on August 21, 2025[1] - "全柴动力" (Code: 600218) reported an announcement on August 21, 2025[1]

Core Viewpoint - The announcement of a cross-industry capital increase has brought significant attention to Huali Family (600503), leading to a volatile stock price movement, with a notable drop following initial gains [1][3] Group 1: Stock Price Movement - Huali Family's stock price experienced a sharp increase followed by a significant decline after the announcement of the investment in Haihe Pharmaceutical [3] - On August 21, the stock opened at 3.6 CNY, peaked at a 0.28% increase, but closed at the daily limit down of 3.23 CNY, reflecting a 10.03% drop [3] - Prior to the decline, the stock had gained over 20% from August 11 to August 20, with two consecutive trading days of limit-up [3] Group 2: Investment Details - Huali Family plans to invest up to 300 million CNY in Haihe Pharmaceutical to acquire approximately 5% to 8.09% of its shares post-financing [1][3] - The investment is part of a broader strategy to explore opportunities in emerging industries, as Huali Family's real estate business faces performance pressures [1][3] - The investment price is set at 4.75 CNY per share, with a maximum subscription of 63.16 million shares [3] Group 3: Financial Performance of Haihe Pharmaceutical - Haihe Pharmaceutical has not yet achieved profitability, reporting revenues of approximately 323 million CNY for 2024 and a net loss of 201 million CNY [10] - The company has three products commercialized but continues to operate at a loss, raising questions about the potential return on investment for Huali Family [10][12] Group 4: Valuation Concerns - The valuation of Haihe Pharmaceutical shows a high premium, with an estimated increase in value of 347.7% to 425.03% based on asset-based valuation methods [7][8] - The Shanghai Stock Exchange has raised concerns regarding the fairness of the transaction price and the absence of performance commitments in the financing plan [7][8] Group 5: Strategic Considerations - Huali Family's decision to invest in Haihe Pharmaceutical is seen as a move to diversify and enhance its core competitiveness amid challenges in the real estate sector [12] - The company believes that the investment will provide new growth opportunities while managing risks associated with the investment [12]

华丽家族股份有限公司 股票交易异常波动公告 证券代码：600503 证券简称：华丽家族 公告编号：临2025－025 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 华丽家族股份有限公司（以下简称"公司"）股票于2025年8月19日、2025 年8月20日连续二个交易日内收盘价格涨幅偏离值累计超过20%。根据《上海证 券交易所交易规则》的有关规定：股票连续三个交易日内收盘价格涨幅偏离值累 计超过20%，属于股票交易异常波动。 ? 经公司自查，并向控股股东、实际控制人核实，截至本公告披露日，除公 司已披露事项外，不存在其他应披露而未披露的重大信息。 ? 敬请广大投资者注意二级市场交易风险，理性决策，审慎投资。 一、股票交易异常波动的具体情况 公司股票于2025年8月19日、2025年8月20日连续二个交易日内收盘价格涨幅 偏离值累计超过20%。根据《上海证券交易所交易规则》的有关规定：股票连续 三个交易日内收盘价格涨幅偏离值累计超过20%，属于股票交易异常波动。 二、公司关注并核实的相关情况 针对公司股票交易 ...